

## RWANDA Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Rwanda										
<b>2. Grant number:</b> 17-RWA-32a-X										
<b>3. Date of Decision Letter:</b> 9 February 2017										
<b>4. Date of the Partnership Framework Agreement:</b> 7 June 2013										
<b>5. Programme title:</b> Injection Safety Devices <sup>1</sup>										
<b>6. Programme duration<sup>2</sup>:</b> 2017										
<b>7. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)										
<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 60%;"></th> <th style="width: 20%;">2017</th> <th style="width: 20%;">Total<sup>3</sup></th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td style="text-align: center;">153,500</td> <td style="text-align: center;">153,500</td> </tr> </tbody> </table>		2017	Total <sup>3</sup>	Programme Budget (US\$)	153,500	153,500				
	2017	Total <sup>3</sup>								
Programme Budget (US\$)	153,500	153,500								
<b>8. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>4</sup>										
<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"><b>TOTAL Injection Safety Devices to be purchased with Gavi funds in each year</b></th> <th style="width: 20%;"><b>2017</b></th> </tr> </thead> <tbody> <tr> <td>Number of AD syringes</td> <td style="text-align: right;">2,991,600</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td style="text-align: right;">47,000</td> </tr> <tr> <td>Number of safety boxes</td> <td style="text-align: right;">33,475</td> </tr> <tr> <td><b>Annual Amounts for Injection Safety Devices for all Gavi vaccines (US\$)</b></td> <td style="text-align: right;"><b>153,500</b></td> </tr> </tbody> </table>	<b>TOTAL Injection Safety Devices to be purchased with Gavi funds in each year</b>	<b>2017</b>	Number of AD syringes	2,991,600	Number of re-constitution syringes	47,000	Number of safety boxes	33,475	<b>Annual Amounts for Injection Safety Devices for all Gavi vaccines (US\$)</b>	<b>153,500</b>
<b>TOTAL Injection Safety Devices to be purchased with Gavi funds in each year</b>	<b>2017</b>									
Number of AD syringes	2,991,600									
Number of re-constitution syringes	47,000									
Number of safety boxes	33,475									
<b>Annual Amounts for Injection Safety Devices for all Gavi vaccines (US\$)</b>	<b>153,500</b>									
<b>Injection Safety Devices to be purchased with Gavi funds in each year, <u>by type of support</u></b>										
<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"><b>New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose per vial LIQUID, Routine</b></th> <th style="width: 20%;"><b>2017</b></th> </tr> </thead> <tbody> <tr> <td>Number of AD syringes</td> <td style="text-align: right;">1,246,500</td> </tr> <tr> <td>Number of safety boxes</td> <td style="text-align: right;">13,725</td> </tr> <tr> <td><b>Annual Amounts for Injection Safety Devices for Vaccine (US\$)</b></td> <td style="text-align: right;"><b>63,000</b></td> </tr> </tbody> </table>	<b>New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose per vial LIQUID, Routine</b>	<b>2017</b>	Number of AD syringes	1,246,500	Number of safety boxes	13,725	<b>Annual Amounts for Injection Safety Devices for Vaccine (US\$)</b>	<b>63,000</b>		
<b>New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose per vial LIQUID, Routine</b>	<b>2017</b>									
Number of AD syringes	1,246,500									
Number of safety boxes	13,725									
<b>Annual Amounts for Injection Safety Devices for Vaccine (US\$)</b>	<b>63,000</b>									

<sup>1</sup> This does not include vaccines.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>4</sup> This is the amount that Gavi has approved.

<b>New Vaccine Support (NVS), DTP-HepB-Hib, 10 doses per vial, LIQUID, Routine</b>	<b>2017</b>
Number of AD syringes	1,008,600
Number of safety boxes	11,100
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	51,000
<b>New Vaccine Support (NVS), HPV Quadrivalent, 1 dose per vial, LIQUID, Routine</b>	<b>2017</b>
Number of AD syringes	330,800
Number of safety boxes	3,650
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	17,000
<b>New Vaccine Support (NVS), Measles Rubella, 10 doses per vial, LYOPHILISED, MSD</b>	<b>2017</b>
Number of AD syringes	405,700
Number of re-constitution syringes	47,000
Number of safety boxes	5,000
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	22,500
<b>9. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
<b>10. Self-procurement:</b> Not applicable	
<b>11. Co-financing obligations:</b> Co-financing requirements are listed in the relevant vaccine Decision Letter.	

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

9 February 2017

## RWANDA

### Support for Health Systems Strengthening (HSS)

This Decision Letter forms part of the PFA and together with the PFA sets out the Programme Terms of the Programme.

<b>1. Country:</b> Rwanda
<b>2. Programme payment grant number:</b> 1318-RWA-10d-Y <b>Performance payment grant number:</b> 16-RWA-10e-Y
<b>3. Date of Decision Letter:</b> 9 February 2017
<b>4. Date of the Partnership Framework Agreement (the "PFA"):</b> 7 June 2013
<p><b>5. Programme: Health Systems Strengthening (HSS)</b></p> <p>For further information about the Programme please refer to:</p> <ul style="list-style-type: none"> <li>• Gavi HSS guidelines and HSS application form available by contacting your Gavi country manager;</li> <li>• Country's approved grant proposal together with any responses to the HSS independent review committee (IRC's) request for clarifications;</li> <li>• The workplan and budget document circulated by email describing the expected Programme Activities and Programme Budget as at the Date of the Decision Letter.</li> </ul>
<p><b>6. Gavi performance based funding</b></p> <p>The Programme shall be subject to Gavi's performance-based funding (PBF). Under this, the HSS support will be split into two payments: the programmed payment (based on implementation of the Programme) and the performance payment (based on improvements in immunisation outcomes). This means that in the first year, Country will receive 100% of the year one annual amount, as an upfront payment. After year one, countries will receive 80% of the annual amount, based on implementation of the grant. Note that countries whose total grant budget would fall below US\$3 million are exempt from this 80% rule.</p> <p>Country will have the opportunity to receive payments beyond the programme budget amount, for exceptional performance. Such performance payments will be based on performance on immunisation outcome indicators. For any given year, the programmed payment and performance payment may total up to 150% of the country's year one annual amount (upfront investment).</p> <p><u>Performance payments for a given year will be made the following year, based on performance of the indicators listed and data verification.</u></p> <p><b>Gavi calculation of performance payments for 2015 achievements – TOTALS:</b></p> <p>Given that Country's DTP3 coverage was <b>at or above 90%</b> at baseline, which is defined as the year prior to the first year of HSS grant implementation, and based on WHO/UNICEF estimates, Country will be rewarded for sustaining high coverage with:</p> <ul style="list-style-type: none"> <li>• 20% of annual country ceiling for maintaining DTP3 coverage at or above 90% and</li> <li>• 20% of annual country ceiling ensuring that 90% of districts have at or above 80% DTP3 coverage.</li> </ul>

Countries with DTP3 coverage >= 90% at baseline					TOTAL Performance payment to the country
Reported DTP3 coverage (WUENIC) at baseline	Eligibility for DTP3 performance payment	Amount of DTP3 performance payment (US\$)	Eligibility for geographic equity performance payment	Amount of geographic equity performance payment (US\$)	
98%	Eligible	492,000	Eligible	492,000	984,000

Should Rwanda wish to request the full details of the calculation method leading to the TOTAL amount of the performance payment, please contact your Gavi senior country manager Antonia Pannell (apannell@gavi.org).

**7. Programme Duration:** 2013 to 2018

**8. Programme Budget:** This is the amount of an estimated multi-year budget endorsed by Gavi under the Programme.

Note that with PBF, annual disbursements may be more or less than these endorsed amounts after the first year.

Programme Year	2013-2016	2017	2018	Total
Programme Budget	US\$ 6,400,840 *	US\$ 1,968,345	US\$ 1,970,785	US\$ 10,339,970

\* US\$ 4,439,957 have been disbursed to date in 2 tranches. 3<sup>rd</sup> tranche (2016) of US\$1,960,883 was approved by October 2015 HLRP but not yet disbursed.

Programme Year	2016**
Performance payment	US\$ 984,000

\*\* 2015 performance payment of US\$ 984,000 was approved by October 2015 HLRP but not yet disbursed.

- 9. Annual Amounts:** This is the estimated annual amount Gavi has approved to be disbursed under the Programme. The Country acknowledges that:
- (a) a proportion of the Annual Amount may be disbursed directly to an agreed implementing agency, such as WHO and UNICEF, rather than to the Country; and
  - (b) each Annual Amount may be disbursed in a number of tranches at quarterly or six-monthly intervals. \*2016 amount (US\$1,960,883) has not been disbursed due to lack of financial reporting.

Programme year	2013-2016	2017
Annual Amount	US\$ 6,400,840	US\$ 1,968,345

Programme year	2016
Performance payment	US\$ 984,000

**10. Outstanding comments/clarifications:** Not applicable

**11. Documents to be delivered:** Not applicable

**12. Other conditions:**

Any requested adjustments to the Annual Amounts will be subject to Gavi approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the Programme. Utilisation of Gavi support stated in this letter will be subject to performance monitoring.

If the bank account information most recently provided to Gavi has changed or changes prior to disbursement, the country will need to complete a bank account information form. Please contact [gavihss@gavi.org](mailto:gavihss@gavi.org) for the form.

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

9 February 2017

**RWANDA**  
**Support for Human Papillomavirus Vaccine (HPV)**

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Rwanda			
<b>2. Vaccines grant number:</b> 1417-RWA-19b-X			
<b>3. Date of Decision Letter:</b> 9 February 2017			
<b>4. Date of the partnership framework agreement:</b> 7 June 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), HPV Routine			
<b>6. Vaccine type:</b> HPV			
<b>7. Requested product presentation and formulation of vaccine:</b> HPV Quadrivalent, 1 dose per vial, LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2014 - 2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)			
	2014-2016	2017	Total <sup>2</sup>
Programme budget	US\$ 4,723,046	US\$ 1,342,500	US\$ 6,065,546
<b>10. Vaccine introduction grant:</b> Not applicable			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>3</sup>			
Type of supplies to be purchased with Gavi funds in each year	2017		
Number of HPV vaccines doses	292,200		
Annual Amounts	US\$ 1,342,500		
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**14. Co-financing obligations:**

Reference code: 1417-RWA-19b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccines doses	13,300
Value of vaccine doses (US\$)	59,841
Total co-financing payments (including freight)	US\$61,500

**15. Operational support for campaigns:** Not applicable**16. Additional reporting requirements:**

Reports other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	As agreed with Secretariat

**17. Financial clarifications:** Not applicable**18. Other conditions:** Not applicable

On behalf of Gavi

Hind Khatib-Othman  
Managing Director, Country Programmes

9 February 2017

## RWANDA Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Rwanda			
<b>2. Grant number:</b> 1517-RWA-09a-X			
<b>3. Date of Decision Letter:</b> 9 February 2017			
<b>4. Date of the Partnership Framework Agreement:</b> 7 June 2013			
<b>5. Programme title:</b> New vaccine support (NVS), MSD as Measles-Rubella			
<b>6. Vaccine type:</b> Measles-Rubella			
<b>7. Requested product presentation and formulation of vaccine:</b> Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
<b>8. Programme duration<sup>1</sup>:</b> 2015 - 2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2015-2016	2017	Total <sup>2</sup>
Programme Budget (US\$)	US\$ 307,000 <sup>3</sup>	US\$123,500	US\$ 430,500
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable.			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>			
Type of supplies to be purchased with Gavi funds in each year	2015-2016	2017	
Number of Measles-Rubella vaccines doses		426,800	
Annual Amounts (US\$)	US\$ 307,000 <sup>5</sup>	US\$123,500	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable.			
<b>14. Co-financing obligations:</b> Not applicable.			
<b>15. Operational support for campaigns:</b> Not applicable.			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



<b>16. Additional reporting requirements:</b> Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b>	
Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.	
	2017
Number of doses of vaccines for Measles Second Dose approved by Gavi.	426,800
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	US\$ 119,504
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	195,908
Number of doses of Measles-Rubella vaccine to be funded by country.	230,892
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	US\$ 140,844
In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.	
In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.	

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

9 February 2017

## RWANDA Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Rwanda			
<b>2. Grant number:</b> 1617-RWA-12c-X			
<b>3. Date of Decision Letter:</b> 9 February 2017			
<b>4. Date of the Partnership Framework Agreement:</b> 7 June 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine			
<b>6. Vaccine type:</b> Pneumococcal			
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose per vial, LIQUID, Pneumococcal (PCV13), 4 doses per vial, LIQUID <sup>1</sup>			
<b>8. Programme duration<sup>2</sup>:</b> 2009 -2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)			
	2009-2016	2017	Total <sup>3</sup>
Programme Budget	US\$ 29,682,948 <sup>4</sup>	US\$ 4,416,000	US\$ 34,098,948
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>5</sup>			
Type of supplies to be purchased with Gavi funds in each year	2009-2016	2017	
Number of Pneumococcal vaccines doses		1,176,100	
Annual Amounts	US\$ 29,682,948 <sup>6</sup>	US\$ 4,416,000	

<sup>1</sup> Country requested a switch to PCV13, 4 dose vial, in 2017. The timing of the first shipments of PCV13, 4 dose vial, will be determined during the development of the 2017 shipment plan based on your desired timing, the stock of the existing presentation of PCV, supply availability, and programmatic readiness to switch. Wastage has been estimated at 10% to align with WHO indicative wastage for the PCV13 4 dose vial and co-financing is aligned with your desired presentation in anticipation of the switch.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>4</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>5</sup> This is the amount that Gavi has approved.

<sup>6</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.									
<b>13. Self-procurement:</b> Not applicable									
<p><b>14. Co-financing obligations:</b>  Reference code: 1617-RWA-12c-X-C  According to the co-financing policy, the Country falls within the group Initial self-financing.  The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2017</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>72,300</td> </tr> <tr> <td>Value of vaccine doses</td> <td>US\$ 238,337</td> </tr> <tr> <td>Total co-financing payments (including freight)</td> <td>US\$ 250,000</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds in each year	2017	Number of vaccine doses	72,300	Value of vaccine doses	US\$ 238,337	Total co-financing payments (including freight)	US\$ 250,000
Type of supplies to be purchased with Country funds in each year	2017								
Number of vaccine doses	72,300								
Value of vaccine doses	US\$ 238,337								
Total co-financing payments (including freight)	US\$ 250,000								
<b>15. Operational support for campaigns:</b> Not applicable									
<p><b>16. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May 2017</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>As agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2017	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	As agreed with Secretariat		
Reports and other information	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2017								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	As agreed with Secretariat								
<b>17. Financial clarifications:</b> Not applicable									
<b>18. Other conditions:</b> Not applicable									

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

9 February 2017

## RWANDA Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Rwanda			
<b>2. Grant number:</b> 1617-RWA-04c-X			
<b>3. Date of Decision Letter:</b> 9 February 2017			
<b>4. Date of the Partnership Framework Agreement:</b> 7 June 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 doses per vial, LIQUID			
<b>8. Programme duration<sup>7</sup>:</b> 2002 -2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)			
	2002-2016	2017	Total <sup>8</sup>
Programme Budget (US\$)	45,652,118 <sup>9</sup>	1,102,500	46,754,618
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>10</sup>			
Type of supplies to be purchased with Gavi funds in each year	2002-2016	2017	
Number of Pentavalent vaccines doses		920,500	
Annual Amounts (US\$)	45,652,118 <sup>11</sup>	1,102,500	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			

<sup>7</sup> This is the entire duration of the Programme.

<sup>8</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>9</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>10</sup> This is the amount that Gavi has approved.

<sup>11</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**14. Co-financing obligations:**

Reference code: 1617-RWA-04c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	185,000
Value of vaccine doses	US\$216,594
Total co-financing payments (including freight)	US\$221,500

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	As agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

9 February 2017

## RWANDA Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Rwanda			
<b>2. Grant number:</b> 17-RWA-13b-X			
<b>3. Date of Decision Letter:</b> 9 February 2017			
<b>4. Date of the Partnership Framework Agreement:</b> 7 June 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine			
<b>6. Vaccine type:</b> Rotavirus			
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose schedule <sup>12</sup>			
<b>8. Programme duration</b> <sup>13</sup> : 2012 -2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)			
	2012-2016	2017	Total <sup>14</sup>
Programme Budget	US\$ 25,673,686 <sup>15</sup>	US\$ 1,370,500	US\$ 27,044,186
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>16</sup>			
Type of supplies to be purchased with Gavi funds in each year	2012-2016	2017	
Number of Rotavirus vaccines doses		609,000	
Annual Amounts	US\$ 25,673,686 <sup>17</sup>	US\$ 1,370,500	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			

<sup>12</sup> Country has elected to switch vaccine product from Rotateq (3 dose schedule) to Rotarix (2 dose schedule) in April 2017.

<sup>13</sup> This is the entire duration of the Programme.

<sup>14</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>15</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>16</sup> This is the amount that Gavi has approved.

<sup>17</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**14. Co-financing obligations:**

Reference code: 17-RWA-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	60,000
Value of vaccine doses	US\$ 130,334
Total co-financing payments (including freight)	US\$ 134,000

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	As agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

9 February 2017